AOTI, Inc. — Director's Dealing 2026

May 1, 2026

National Storage Mechanism | Additional information

RNS Number : 6582C

AOTI, Inc.

01 May 2026

1 May 2026

AOTI, INC. (the "Company" or "Group" or "AOTI")

Employee Share Purchase Plan

AOTI, INC. (AIM: AOTI), a medical technology group focused on delivering outcomes-based care at home, by more durable healing of wounds and the prevention of amputations, announces the establishment of an Employee Share Purchase Plan (ESPP). CSC Global1 is acting as administrator of and trustee to, the ESPP.

The principal terms of the plan are as follows:

i.    Eligible employees elect to contribute for twelve months up to a maximum monthly value of either GBP 300, USD 400 or EUR 350, which is deducted from after tax pay and used to purchase Investment Shares.

ii.    Existing common shares ("Investment Shares") are acquired by the trustee quarterly at the prevailing market price on behalf of participating employees.

iii.   One new common share ("Matching Share") will be awarded to employees at nil cost for every four Investment Shares purchased.

iv.   There is a three-year vesting period from the commencement of the ESPP to qualify for Matching Shares.

v.    Matching Shares will be forfeited under certain conditions such as if an employee leaves AOTI or sells the Investment Shares before the end of the vesting period.

On 30 April 2026, the following PDMRs of the Company enrolled in the ESPP and have committed to monthly contributions for twelve months as per the table below:

PDMR	Role	Monthly Contribution
Mike Griffiths	Chief Executive Officer	USD400
Jayesh Pankhania	Chief Financial Officer	GBP300
Anthony Moffatt	Chief Operating Officer	EUR350

1CSC Global operates through CSC Employee Benefit Trustee (Jersey) Limited and CSC Employee Benefit Services (Jersey) Limited

For more information:

AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer	+44 (0)20 3727 1000 [email protected]
Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel	+44 (0)20 7418 8900
Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden	+44 (0)20 3100 2000
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins	+44 (0)20 3727 1000 [email protected]

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO2® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCWPUWACUPQGCU